共 50 条
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy
被引:108
|作者:
Schrempf, Anna
[1
,2
]
Slyskova, Jana
[1
,2
]
Loizou, Joanna, I
[1
,2
]
机构:
[1] Austrian Acad Sci, CeMM Res Ctr Mol Med, Lazarettgasse 14,AKH BT 25-3, A-1090 Vienna, Austria
[2] Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria
来源:
基金:
欧洲研究理事会;
关键词:
DOUBLE-STRAND BREAKS;
BASE EXCISION-REPAIR;
HOMOLOGOUS-RECOMBINATION;
POL-THETA;
LIGASE-III;
HELICASE DOMAIN;
CELLS;
RESISTANCE;
TUMORS;
BYPASS;
D O I:
10.1016/j.trecan.2020.09.007
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Targeted cancer therapies represent a milestone towards personalized treatment as they function via inhibition of cancer-specific alterations. Polymerase theta (POLQ), an error-prone translesion polymerase, also involved in DNA double-strand break (DSB) repair, is often upregulated in cancer. POLQ is synthetic lethal with various DNA repair genes, including known cancer drivers such as BRCA1/2, making it essential in homologous recombination-deficient cancers. Thus, POLQ represents a promising target in cancer therapy and efforts for the development of POLQ inhibitors are actively underway with first clinical trials due to start in 2021. This review summarizes the journey of POLQ from a backup DNA repair enzyme to a promising therapeutic target for cancer treatment.
引用
收藏
页码:98 / 111
页数:14
相关论文